论文部分内容阅读
目的:观察薄芝糖肽联合利巴韦林治疗小儿手足口病的疗效及安全性。方法:将小儿手足口病普通型186例随机分为治疗组106例和对照组80例,两组均采用相同的基础治疗。治疗组用薄芝糖肽2 mL/次加入5%葡萄糖50～100 mL静脉滴注,1次/d,同时给予利巴韦林10 mg/kg加入5%葡萄糖100～150 mL中静脉滴注,1次/d。对照组仅给予利巴韦林治疗,剂量同上。结果:治疗组退热时间、口腔疼痛消失时间、皮疹消失时间、平均住院天数、并发症发生率均少于对照组,两组比较差异有统计学意义(P<0.01)。结论:薄芝糖肽联合利巴韦林治疗小儿手足口病疗效确切,不良反应少。
OBJECTIVE: To observe the efficacy and safety of the combination of baozhi glycopeptide and ribavirin in the treatment of hand-foot-mouth disease in children. Methods: 186 children with HFMD were randomly divided into treatment group (n = 106) and control group (n = 80). Both groups adopted the same basic treatment. In the treatment group, intravenous drip of 50 ~ 100 mL 5% dextrose and 2 mL / min of bolus glycopeptide were added to the treated group, once / d, while Ribavirin 10 mg / kg was added to 100 ~ 150 mL of 5% , 1 time / d. The control group was given ribavirin only, the same dose as above. Results: The treatment group fever, oral pain disappear time, rash disappear time, the average length of stay in hospital, complications were less than the control group, the difference between the two groups was statistically significant (P <0.01). Conclusion: The combination of BTP plus ribavirin has a good curative effect in children with hand-foot-mouth disease and few adverse reactions.